Format

Send to

Choose Destination
Vaccine. 2013 Dec 17;32(1):39-47. doi: 10.1016/j.vaccine.2013.10.080. Epub 2013 Nov 6.

A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Author information

1
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
2
Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
3
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, United States; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, United States. Electronic address: dbriles@uab.edu.

Abstract

Streptococcus pneumoniae causes otitis media, meningitis and pneumonia in patients worldwide; predominantly affecting young children, the elderly, and the immune compromised. Current vaccines against invasive pneumococcal disease are based on the polysaccharide capsules of the most clinically relevant serotypes. Due to serotype replacement, non-vaccine serotypes of S. pneumoniae have become more clinically relevant and as a result pneumococcal vaccines are becoming increasingly complex. These events emphasize the need to evaluate the potential for pneumococcal cross-reactive proteins to contribute to future vaccines. Antibody elicited by the immunization of humans with pneumococcal surface protein A (PspA) can passively protect mice from infection. However, robust in vitro functional assays for antibody to PspA are not available to predict the protective capacity of immune serum. For polysaccharide based vaccines, a standardized opsonophagocytosis killing assay (OPKA) is used. Antibody to PspA, however, does not work well in the standard OPKA. The present studies take advantage of past observations that phagocytosis is more efficient on tissue surfaces than in solution. In a modified surface killing assay (MSKA), monoclonal antibody to PspA, in the presence of complement, opsonized pneumococci for killing by phagocytes on an agar surface. Five monoclonal antibodies to PspA were tested; three demonstrated increased amounts of killing compared to the diluent control and protected mice by passive protection against type 3 pneumococci. The two antibodies that were not functional in the MSKA also failed to protect mice. Thus, an MSKA might be useful as a functional assay for immunity to PspA.

KEYWORDS:

Functional assay; Pneumococcal surface protein A; Polymorphonuclear leukocytes; PspA; Streptococcus pneumoniae; Surface killing assay

PMID:
24211169
PMCID:
PMC3893085
DOI:
10.1016/j.vaccine.2013.10.080
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center